BRIEF-Novo reports positive results from phase 3 trial with NovoEight

COPENHAGEN, March 19 Wed Mar 19, 2014 8:37am EDT

Related Topics

COPENHAGEN, March 19 (Reuters) - Danish pharmaceutical group Novo Nordisk A/S said on Wednesday: * Reports positive results from first phase 3 trial with N8-GP, a

long-acting factor VIII for treatment of haemophilia A patients, 12 years or older * N8-GP appeared to have a safe profile and to be well tolerated * Among the 186 patients in the trial, one patient who responded well to prophylactic treatment throughout the trial developed an FVIII inhibitor. This is in line with expectations in a population of previously treated haemophilia A patients. * Novo is expecting the three remaining trials in the programme to be finalised within the next 12 months. Source text for Eikon:

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

A tourist takes a plunge as she swims at Ngapali Beach, a popular tourist site, in the Thandwe township of the Rakhine state, October 6, 2013. Picture taken October 6, 2013. REUTERS/Soe Zeya Tun (MYANMAR - Tags: SOCIETY) - RTR3FOI0

Where do you want to go?

We look at when to take trips, budget considerations and the popularity of multigenerational family travel.   Video